A complete guide to financial resources and support for patients and caregivers

s presented at the Presidential Symposium elucidating haplotypes in myeloproliferative disorders, highthroughput RNA interference screening, and gene mutations or deletions. Genomic research that may not seem to have immediate clinical relevance often spurs the development of new agents targeting molecules that infl uence the pathology of human malignancies, such as STK33 inhibitors. On closer examination, the selected abstracts will likely do just that. We summarize the 4 oncologyrelated “best” abstracts. JAK2V617F mutations in myeloproliferative neoplasms Jones and colleagues investigated the role of inherited factors in myeloproliferative neoplasms by analyzing haplotypes within the Janus kinase 2, or JAK2, gene. They followed the recent knowledge trail demonstrating that the V617F mutation in JAK2 occurs frequently in patients with such neoplasms (Table on page 10). This tyrosine kinase activates cell-signaling pathways to transform hematopoietic progenitors. The data from the Jones Our New Logo Oncology is an ever-changing fi eld, and here at Oncology & Biotech News, we felt it was a good time to change our logo. Over the next few months, we plan to make various updates to our look and format, all with the goal of improving how we bring you information. Your satisfaction is important to us, so please let us know what you like—and don’t like. You can send us an e-mail at